Stocktwits on MSN2h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...
A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
First for Women on MSN19h
Ozempic Now FDA-Approved for Kidney Disease-Here's What to KnowGLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback